---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000167"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:09:54.468836+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Coherus provides preliminary Q4/FY2024 revenue and cash; UDENYCA allocated due to strong demand

## Summary
- Preliminary unaudited net revenues for Q4 and FY2024 presented at J.P. Morgan Healthcare Conference.
- Cash, cash equivalents and investments as of Dec 31, 2024 disclosed; final results may materially differ.
- All three presentations of UDENYCA temporarily allocated due to strong demand in Q4 2024 and into Q1 2025.
- Financial closing procedures not yet complete; independent auditor has not reviewed these preliminary results.

## SEC filing metadata
- accession: 0001558370-25-000167
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025000167/0001558370-25-000167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025000167/chrs-20250113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000167
- JSON: https://secwatch.observer/filing/0001558370-25-000167.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.